Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITII: 90Y-anti-CD66 in High-Risk Pediatric Leukemia
NCT04856215Phase 2Unknown
- Sponsor
- Great Ormond Street Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 90Y-besilesomab in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and juvenile myelomonocytic leukemia (JMML), sponsored by Great Ormond Street Hospital. Primary endpoint: Disease response after 90Y-labelled anti-CD66 monoclonal antibody. Status: unknown.
02
Drugs
90Y-besilesomab
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT04856215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856215.